Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction ; volume:408 ; number:1 ; day:6 ; month:9 ; year:2023 ; pages:1-11 ; date:12.2023
Langenbeck's archives of surgery ; 408, Heft 1 (6.9.2023), 1-11, 12.2023
- Creator
-
Feka, Joy
Jomrich, Gerd
Winkler, Daniel
Ilhan-Mutlu, Ayseguel
Kristo, Ivan
Paireder, Matthias
Rieder, Erwin
Bologheanu, Milena
Asari, Reza
Schoppmann, Sebastian Friedrich
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00423-023-03093-y
- URN
-
urn:nbn:de:101:1-2023111714202211411694
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Feka, Joy
- Jomrich, Gerd
- Winkler, Daniel
- Ilhan-Mutlu, Ayseguel
- Kristo, Ivan
- Paireder, Matthias
- Rieder, Erwin
- Bologheanu, Milena
- Asari, Reza
- Schoppmann, Sebastian Friedrich
- SpringerLink (Online service)
Other Objects (12)
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma
Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma
Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma
Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis